Liquid Biopsy Lung Cancer Test
Cost: 6000.0 AED
Test Components
Streck Tube
Sample Condition
Blood
Report Delivery
21 Working Days
Method
NGS (Next-Generation Sequencing)
Test Type
Genetics
Doctor
General Physician
Test Department
Genetic Lab
Pre Test Information
This test requires a biopsy sample.
Test Details
Liquid biopsy is a non-invasive diagnostic test used to detect lung cancer by analyzing a sample of blood. The test is based on the detection of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) released by tumor cells into the bloodstream. CTCs are cancer cells that have detached from the primary tumor and entered the bloodstream, while cfDNA is DNA that is released into the bloodstream by dying cancer cells. These biomarkers can be detected and analyzed using advanced molecular techniques to identify specific genetic mutations or alterations that are associated with lung cancer.
The liquid biopsy test can be used to monitor the progression of lung cancer, detect early relapse, and guide treatment decisions. It is less invasive than traditional biopsy methods and can be performed more frequently, allowing for more precise monitoring of the disease. The liquid biopsy test has shown promising results in clinical trials and is expected to become an important tool in the diagnosis and management of lung cancer.
Test Name | Liquid Biopsy Lung Cancer Test |
---|---|
Components | Streck Tube |
Price | 6000.0 AED |
Sample Condition | Blood |
Report Delivery | 21 Working Days |
Method | NGS |
Test type | Genetics |
Doctor | General Physician |
Test Department: | |
Pre Test Information | Require Biopsy Sample for this test |
Test Details |
Liquid biopsy is a non-invasive diagnostic test used to detect lung cancer by analyzing a sample of blood. The test is based on the detection of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) released by tumor cells into the bloodstream. CTCs are cancer cells that have detached from the primary tumor and entered the bloodstream, while cfDNA is DNA that is released into the bloodstream by dying cancer cells. These biomarkers can be detected and analyzed using advanced molecular techniques to identify specific genetic mutations or alterations that are associated with lung cancer. The liquid biopsy test can be used to monitor the progression of lung cancer, detect early relapse, and guide treatment decisions. It is less invasive than traditional biopsy methods and can be performed more frequently, allowing for more precise monitoring of the disease. The liquid biopsy test has shown promising results in clinical trials and is expected to become an important tool in the diagnosis and management of lung cancer. |